^
    9d
    HDAC inhibitors reverse YAP-driven immune resistance in NSCLC: mechanistic and translational evidence. (PubMed, J Immunother Cancer)
    YAP is a strong predictive biomarker of response to immunotherapy in NSCLC. The combination of TD and ICIs shows promise in reversing immunotherapy resistance associated with high YAP expression, offering a potential strategy to overcome acquired resistance.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • YAP1 (Yes associated protein 1) • SNAI2 (Snail Family Transcriptional Repressor 2)
    |
    Epidaza (chidamide)
    10d
    DEL-MRD-CHID: Chidamide Maintenance for MRD-Positive Double-Expressor DLBCL in First Complete Remission (clinicaltrials.gov)
    P2, N=69, Recruiting, Rong Tao | Not yet recruiting --> Recruiting
    Enrollment open • Minimal residual disease • Circulating tumor DNA
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Epidaza (chidamide)
    12d
    Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) (clinicaltrials.gov)
    P2, N=32, Active, not recruiting, Liping Dou
    New P2 trial
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    cytarabine • azacitidine • Epidaza (chidamide)
    13d
    Venetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid Leukaemia (clinicaltrials.gov)
    P2, N=120, Recruiting, Chinese PLA General Hospital | Trial primary completion date: Dec 2027 --> Sep 2027
    Trial primary completion date
    |
    Venclexta (venetoclax) • cytarabine • azacitidine • Epidaza (chidamide) • daunorubicin • aclarubicin
    16d
    Chidamide Combined With Toripalimab in Sarcoma (clinicaltrials.gov)
    P2, N=73, Completed, Sun Yat-sen University | Recruiting --> Completed | Trial completion date: Dec 2024 --> Apr 2026 | Trial primary completion date: Dec 2023 --> Oct 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    Loqtorzi (toripalimab-tpzi) • Epidaza (chidamide)
    17d
    Chidamide, Venetoclax, Azacitidine, and Homoharringtonine for High-risk Fit AML (clinicaltrials.gov)
    P2, N=46, Not yet recruiting, Dongguan People's Hospital
    New P2 trial
    |
    Venclexta (venetoclax) • cytarabine • azacitidine • Epidaza (chidamide) • Synribo (omacetaxine mepesuccinate)
    17d
    Case Report: Cutaneous niche-restricted malignant phenotypes in PTCL-NOS revealed by single-cell sequencing. (PubMed, Front Oncol)
    Despite CHOP, CHOEP, DA-EPOCH, and AC-CHOP (azacitidine plus chidamide) regimens, the patient experienced primary refractory disease and died 6 months from diagnosis following COVID-19 superinfection. To our knowledge, this is the first case reporting single-cell transcriptomic comparison of skin versus blood compartments in PTCL-NOS, revealing how cutaneous microenvironment sculpts aggressive malignant phenotypes and providing potential targets for compartment-specific therapy.
    Journal
    |
    IL17A (Interleukin 17A)
    |
    azacitidine • Epidaza (chidamide)
    18d
    A novel therapeutic avenue: pharmacological induction of tumor cell pyroptosis. (PubMed, Am J Cancer Res)
    For example, a recent study in Communications Medicine has demonstrated that histone deacetylase inhibitors de-repress transcription of a tumor suppressor GSDME in B-cell lymphoma cells, and synergize with cisplatin and etoposide to promote GSDME cleavage by caspase-3 and subsequent pyroptosis of lymphoma cells. Furthermore, the anti-lymphoma efficacy of this combination therapy in vivo depends on CD8 T cells. This article provides a brief introduction of the pyroptosis pathway in cancer, comments on this promising 'One action, two benefits' therapeutic strategy for cancer treatment, and discusses the significance and unaddressed questions in recent therapeutic studies targeting pyroptosis-suppressing mechanisms in cancer.
    Journal
    |
    CASP3 (Caspase 3) • GSDME (Gasdermin E)
    |
    cisplatin • etoposide IV • Epidaza (chidamide)
    19d
    A Clinical Study Evaluating the Safety, Tolerability, and Effect on HIV Reservoir of Ibalizumab Combined With Chidamide (a Histone Deacetylase Inhibitor) in People Living With HIV (clinicaltrials.gov)
    P1, N=18, Not yet recruiting, First Affiliated Hospital of Zhejiang University
    New P1 trial
    |
    CD4 (CD4 Molecule)
    |
    Yervoy (ipilimumab) • Epidaza (chidamide)
    24d
    Phase II Study of Chidamide-Dinutuximab Beta-Irinotecan-Temozolomide for Refractory/Relapsed Neuroblastoma in Children (clinicaltrials.gov)
    P2, N=27, Recruiting, Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    temozolomide • irinotecan • Epidaza (chidamide) • Qarziba (dinutuximab beta)
    27d
    Chidamide Monotherapy for Intermediate-to-High-Risk Myelodysplastic Syndromes (clinicaltrials.gov)
    P2, N=15, Not yet recruiting, Zhongshan Hospital (Xiamen), Fudan University
    New P2 trial
    |
    Epidaza (chidamide)
    30d
    MA-BC-II-047: Exploration of Dalpiciclib + Chidamide in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor: a Phase Ⅰb Study (clinicaltrials.gov)
    P1, N=22, Completed, Beijing 302 Hospital | Trial completion date: Nov 2025 --> Mar 2026 | Trial primary completion date: Nov 2024 --> Dec 2025 | Not yet recruiting --> Completed
    Trial completion • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Epidaza (chidamide) • AiRuiKang (dalpiciclib)